⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947978 | 1.00 | TDP1 (0.35) | — | |
| SCHEMBL9062083 | 0.92 | PLG (0.34) | — | |
| SCHEMBL329988 | 0.88 | — | — | |
| SCHEMBL2650273 | 0.88 | — | — | |
| SCHEMBL1423045 | 0.87 | ALDH1A1 (0.38) | — | |
| SCHEMBL26844559 | 0.87 | PLG (0.37) | — | |
| SCHEMBL28545306 | 0.87 | ALDH1A1 (0.31) | — | |
| SCHEMBL10786303 | 0.87 | TSHR (0.35) | — | |
| SCHEMBL14328073 | 0.87 | PLG (0.52) | — | |
| SCHEMBL10608274 | 0.86 | EPHX1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4731630-A1 | HOMOPHTHALAZINONE INDOLE PARP INHIBITORS AND METHODS OF USE | Valo Health, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3986553-B1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4692079-A1 | CYP11A1 INHIBITOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12516061-B2 | Tricyclic Janus kinase 1 inhibitors, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-01-06 | — | — | US | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250380697-A1 | ISOXAZOLINE DERIVATIVE COMPOUND AND INSECTICIDAL COMPOSITION COMPRISING SAME | KYUNG NONG CORPORATION (KR) | 2025-12-18 | — | — | US | disclosed |
| WO-1992020227-A1 | SUBSTITUTED ORALLY EFFECTIVE ION CHELATORS RELATED TO DEFEROXAMINE | ORAL-D (US) | 1992-11-26 | — | — | WO | disclosed |
| US-5047421-A | Treating trivalent metal overload conditions in humans | ORAL-D (US) | 1991-09-10 | — | — | US | disclosed |
| US-5015664-A | Orally effective ion chelators related to deferoxamine | ORAL D (US) | 1991-05-14 | — | — | US | disclosed |
| US-4684482-A | DEFEROXAMINE DERIVATIVES | ORAL-D (L.P.) (US) | 1987-08-04 | — | — | US | disclosed |
| US-4671901-A | DIFEROXAMINE DERIVATIVES FOR REDUCTION OF METAL ION TUSSUE OV ERLOAD | ORAL-D (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0171414-A1 | ORALLY EFFECTIVE ION CHELATORS RELATED TO DEFEROXAMINE. | ORAL D (US) | 1986-02-19 | — | — | EP | disclosed |
| WO-1985003290-A1 | ORALLY EFFECTIVE ION CHELATORS RELATED TO DEFEROXAMINE | ORAL-D (US) | 1985-08-01 | — | — | WO | disclosed |
| US-4108857-A | CNS DEPRESSANTS, ANALGESICS, PSYCHOMOTOR ACTION | STERLING DRUG INC. (US) | 1978-08-22 | — | — | US | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-3966747-A | NARCOTIC AGONIST ANDOR ANTAGONIST ACTIVITY | BRISTOL-MYERS COMPANY (US) | 1976-06-29 | — | — | US | disclosed |